Is miR therapeutic targeting still a miRage?

Since the discovery of the first microRNA (miR), almost three decades ago, the roles played by miRs under normal and diseased settings have been widely investigated. miRs are found to play crucial roles in cancer initiation and progression, as well as towards therapy response mechanisms. Therefore,...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in bioscience (Landmark. Print) Vol. 26; no. 10; pp. 680 - 692
Main Author Levantini, Elena
Format Journal Article
LanguageEnglish
Published Singapore IMR Press 30.10.2021
Subjects
biomarkers
cancer
Humans
MicroRNAs - genetics
mir-21
Neoplasms - drug therapy
Neoplasms - genetics
nsclc
rna therapeutics
Biomarkers
RNA therapeutics
miR-21
NSCLC
Cancer
Online AccessGet full text

Cover

More Information
Summary:Since the discovery of the first microRNA (miR), almost three decades ago, the roles played by miRs under normal and diseased settings have been widely investigated. miRs are found to play crucial roles in cancer initiation and progression, as well as towards therapy response mechanisms. Therefore, they are relevant and attractive targets for therapeutic development. Many preclinical studies have demonstrated their promise as future anti-cancer tools. Recently, increasing number of early phase clinical trials have emerged. In this Commentary, we will summarize the major discoveries within the miR research field and highlight the of current miR-therapeutics, which has prominent potential of impacting future cancer regimens given their massive dysregulation in oncogenic processes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2768-6701
2768-6698
DOI:10.52586/4979